A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants
Study Identifier:
ALXN1830-HV-105
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1830
- Drug: Placebo
Date
Nov 2019 - Jan 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years
Requirements Information
Sex
Female & Male
Age
18 - 65 Years
Study Details
Medical Condition
- Other
Study Drug
- Drug: ALXN1830
- Drug: Placebo
Date
Nov 2019 - Jan 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 65 Years years
Requirements Information
Protocol Summary
This study will evaluate the effects of single ascending doses (SAD) and multiple ascending doses (MAD) of ALXN1830 administered subcutaneously (SC) to healthy adult participants.
Trial Locations
Location
Status
Location
Clinical Trial Site
London, United Kingdom
Status
N/A